Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxecitine SCHEMBL29910618 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL30616799 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL15832461 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL887491 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL10238960 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL31503186 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23346798 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL13700553 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23178 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL2623809 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630822-B2 | Treatment of heart failure in human subjects | NOVO NORDISK A/S (DK) | 2026-05-19 | — | — | US | claimed |
| US-20250264459-A1 | IN VITRO ASSAY TO PREDICT CARDIOTOXICITY | STEMINA BIOMARKER DISCOVERY INC (US) | 2025-08-21 | — | — | US | claimed |
| EP-4578501-A1 | TREATMENT OF HEART FAILURE IN HUMAN SUBJECTS | Novo Nordisk A/S (DK) | 2025-07-02 | — | — | EP | claimed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| EP-3983066-B1 | TREATMENT OF HEART FAILURE AND FIBROSIS IN HUMAN SUBJECTS | NOVO NORDISK AS (DK) | 2025-03-05 | — | — | EP | claimed |
| US-20220243204-A1 | TREATMENT OF HEART FAILURE IN HUMAN SUBJECTS | NOVO NORDISK A/S (DK) | 2022-08-04 | — | — | US | claimed |
| US-20220162597-A1 | Compound for treatment of heart failure | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-05-26 | — | — | US | claimed |
| EP-3983066-A1 | TREATMENT OF HEART FAILURE IN HUMAN SUBJECTS | Cardior Pharmaceuticals GmbH (DE) | 2022-04-20 | — | — | EP | claimed |
| EP-3724336-B1 | IMPROVED COMPOUND FOR TREATMENT OF HEART FAILURE | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-02-09 | — | — | EP | claimed |
| US-11208651-B2 | Compound for treatment of heart failure | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2021-12-28 | — | — | US | claimed |
| WO-2002060454-A2 | USE OF DINUCLEOSIDE POLYPHOSPHATE TO STIMULATE REMOVAL OF FLUID IN RETINAL DISORDERS | INSPIRE PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | claimed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | claimed |
| US-6258941-B1 | METAL COMPLEX COVALENTLY LINKED TO NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE; COMPLEX IS CAPABLE OF HYDROLYZING RNA; SYNTHETIC RIBOZYMES/ANTISENSE AGENTS FOR GENE EXPRESSION INHIBITION | WASHINGTON UNIVERSITY | 2001-07-10 | — | — | US | claimed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| US-5776488-A | PHOSPHOLIPID, WATER SOLUBILE 2'-DEOXYCYTIDINE, STEROL, STEARYLAMINE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-07-07 | — | — | US | claimed |
| EP-0420862-B1 | PHARMACEUTICAL COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES FOR WOUND HEALING | PRO NEURON INC (US) | 1993-11-24 | — | — | EP | claimed |
| EP-0533753-A1 | RNA HYDROLYSIS/CLEAVAGE | WASHINGTON UNIVERSITY (US) | 1993-03-31 | — | — | EP | claimed |
| WO-1991019730-A1 | RNA HYDROLYSIS/CLEAVAGE | MONSANTO COMPANY (US) | 1991-12-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630822-B2 | Treatment of heart failure in human subjects | SLC5A2, SLC5A1, DPP4 | DNMT1 1354/4885ADRB1 153/4885POLB 2111/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | DNMT1 3266/4885ADRB1 1237/4885POLB 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.